390 related articles for article (PubMed ID: 8841152)
1. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
3. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
4. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
5. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
8. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.
Desmeules JA; Oestreicher MK; Piguet V; Allaz AF; Dayer P
J Pharmacol Exp Ther; 1999 Feb; 288(2):607-12. PubMed ID: 9918565
[TBL] [Abstract][Full Text] [Related]
11. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
12. The antitussive effect of dextromethorphan in relation to CYP2D6 activity.
Abdul Manap R; Wright CE; Gregory A; Rostami-Hodjegan A; Meller ST; Kelm GR; Lennard MS; Tucker GT; Morice AH
Br J Clin Pharmacol; 1999 Sep; 48(3):382-7. PubMed ID: 10510150
[TBL] [Abstract][Full Text] [Related]
13. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
14. Induction of CYP2D6 in pregnancy.
Wadelius M; Darj E; Frenne G; Rane A
Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
[TBL] [Abstract][Full Text] [Related]
15. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
17. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
18. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
19. Influence of concomitant quinidine administration on dextromethorphan disposition in rats.
Marier JF; Pope LE; Yakatan GJ; Berg JE; Stiles M; Vachon P
J Vet Pharmacol Ther; 2004 Apr; 27(2):111-4. PubMed ID: 15096109
[TBL] [Abstract][Full Text] [Related]
20. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
